 Home > Active Ingredient News > Immunology News > ARD: Prevention of disease flares by risk adaptation stratification of treatment withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial

ARD: Prevention of disease flares by risk adaptation stratification of treatment withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial

 Last Update: 2022-08-16
 Source: Internet
 Author: User

Tags

cloning methods

hr 100

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Objective : The decision to discontinue treatment in clinical remission of juvenile idiopathic arthritis remains challengi.

Objectives : The decision to discontinue treatment in clinical remission of juvenile idiopathic arthritis remains challengi.

Methods : This multicenter trial (PREVENT-JIA) enrolled 119 patients with JIA in clinical remission , 100 of whom entered the intervention phase to continue or discontinue treatment based on S100A12 and hsCRP level.

METHODS : This multicenter trial ( PREVENT-JIA) enrolled 119 patients with JIA in clinical remission , 100 of whom entered the intervention phase to continue or discontinue treatment based on S100A12 and hsCRP level.

RESULTS: In the PREVENT-JIA arm, 49 patients experienced seizures, and 45% of discontinued patients experienced seizures within the next 12 mont.

Conclusion The biomarker-guided treatment withdrawal strategy is feasible in clinical practi.

Gerss J, Tedy M, Klein A , et a.
Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA tri.
Annals of the Rheumatic Diseases2022; 81: 990-99 , et al Annals of the Rheumatic Diseases81: leave a comment here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

High Purity 99% BPN14770 Zatolmilast 1606974-33-7 In Stock Fast Ship to USA

CAS No.: 1606974-33-7

Pharm Grade

$1-1.1/UNIT FOB

High quality Thymosin α1 Pure CAS 62304-98-7 Thymosin Alpha 1 Thymalfasin

CAS No.: 62304-98-7

Pharmacy Grade

$12-15/UNIT FOB

Top quantity Imiquimod CAS NO 99011-02-6 White crystalline powder 99% API

CAS No.: 99011-02-6

Pharmacy Grade

$1800-1850/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.